These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36729892)

  • 1. Anlotinib in patients with relapsed or refractory thymic epithelial tumors: a study of 50 cases.
    Wang CL; Zhao YZ; Zhang Q; Zeng WQ; Jia TY; Zhu L; Fang WT; Fu XL
    Anticancer Drugs; 2023 Aug; 34(7):852-856. PubMed ID: 36729892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab in combination with paclitaxel and platinum for previously treated advanced thymic epithelial tumors.
    Wang CL; Gao LT; Lyu CX; Zhang Q; Zeng WQ; Fang WT; Zhu L; Fu XL
    Med Oncol; 2022 Jan; 39(2):25. PubMed ID: 34982283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21).
    Jung HA; Kim M; Kim HS; Kim JH; Choi YH; Cho J; Park JH; Park KU; Ku BM; Park S; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2023 Feb; 18(2):223-231. PubMed ID: 36307042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
    Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
    Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A Retrospective Analysis.
    Li S; Zhou H; Zhang X; Bu B; Tao R; Zhang H; Yu J
    Recent Pat Anticancer Drug Discov; 2023; 18(4):528-537. PubMed ID: 36415100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.
    Antonarelli G; Corti C; Zucali PA; Perrino M; Manglaviti S; Lo Russo G; Varano GM; Salvini P; Curigliano G; Catania C; Conforti F; De Pas T
    Eur J Cancer; 2022 Oct; 174():31-36. PubMed ID: 35970033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
    Tsukita Y; Inoue A; Sugawara S; Kuyama S; Nakagawa T; Harada D; Tanaka H; Watanabe K; Mori Y; Harada T; Hino T; Fujii M; Ichinose M
    Lung Cancer; 2020 Jan; 139():89-93. PubMed ID: 31751805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma.
    Wang Y; Nie J; Dai L; Hu W; Chen X; Han J; Ma X; Tian G; Han S; Long J; Zhang Z; Fang J
    Thorac Cancer; 2019 Jan; 10(1):17-23. PubMed ID: 30411854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule multitarget antiangiogenic inhibitor treatments for advanced thymic epithelial tumors: A retrospective study.
    Shen W; Jin Y; Yu Y; Chen N; Fan Y
    Thorac Cancer; 2024 Jan; 15(2):122-130. PubMed ID: 38011005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The relationship between myasthenia gravis and the different pathological type of thymoma patients' operation and prognosis].
    Zhang Y; Yu L; Jing Y; Ke J
    Zhonghua Wai Ke Za Zhi; 2015 Aug; 53(8):612-6. PubMed ID: 26653963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.
    Cho J; Kim HS; Ku BM; Choi YL; Cristescu R; Han J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    J Clin Oncol; 2019 Aug; 37(24):2162-2170. PubMed ID: 29906252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.
    Remon J; Girard N; Mazieres J; Dansin E; Pichon E; Greillier L; Dubos C; Lindsay CR; Besse B
    Lung Cancer; 2016 Jul; 97():99-104. PubMed ID: 27237035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
    Rajan A; Carter CA; Berman A; Cao L; Kelly RJ; Thomas A; Khozin S; Chavez AL; Bergagnini I; Scepura B; Szabo E; Lee MJ; Trepel JB; Browne SK; Rosen LB; Yu Y; Steinberg SM; Chen HX; Riely GJ; Giaccone G
    Lancet Oncol; 2014 Feb; 15(2):191-200. PubMed ID: 24439931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors.
    Kim HS; Lee JY; Lim SH; Sun JM; Lee SH; Ahn JS; Park K; Moon SH; Ahn MJ
    J Thorac Oncol; 2015 Dec; 10(12):1800-6. PubMed ID: 26484631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience.
    Bluthgen MV; Boutros C; Fayard F; Remon J; Planchard D; Besse B
    Lung Cancer; 2016 Sep; 99():111-6. PubMed ID: 27565923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803.
    Inoue A; Sugawara S; Harada M; Kobayashi K; Kozuki T; Kuyama S; Maemondo M; Asahina H; Hisamoto A; Nakagawa T; Hotta K; Nukiwa T
    J Thorac Oncol; 2014 Dec; 9(12):1805-9. PubMed ID: 25393793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
    Hirai F; Seto T; Yamanaka T; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
    Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary thymic epithelial neoplasms showing combined features of thymoma and thymic carcinoma. A clinicopathologic study of 22 cases.
    Suster S; Moran CA
    Am J Surg Pathol; 1996 Dec; 20(12):1469-80. PubMed ID: 8944040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological Findings in Myasthenia Gravis Patients with Thymic Hyperplasia and Thymoma.
    Chen P; Wang YP; Mou DL; Li ZY; Qu QM; Wang HY; Deng Y; Li XF; Wang T; Xu XH; Zhao G
    Pathol Oncol Res; 2018 Jan; 24(1):67-74. PubMed ID: 28299711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy between B3 Thymoma and Thymic Carcinoma.
    Hao Y; Si J; Jin J; Wei J; Xiang J; Xu C; Song Z
    Curr Oncol; 2022 Dec; 29(12):9452-9460. PubMed ID: 36547157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.